Comparative Pharmacology
Head-to-head clinical analysis: LIQUAMAR versus XARELTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAMAR versus XARELTO.
LIQUAMAR vs XARELTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liquamar (phenprocoumon) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver by blocking the reduction of vitamin K to its active hydroquinone form.
Direct factor Xa inhibitor that selectively blocks the active site of factor Xa, inhibiting thrombin generation and thrombus formation.
Initial: 0.5-1 mg/kg IV (not to exceed 2 mg). Maintenance: 0.5-2 mg IV q8-12h based on INR.
15 mg orally twice daily for 21 days, then 20 mg orally once daily; for atrial fibrillation: 20 mg orally once daily with food; for VTE prophylaxis in hip or knee replacement: 10 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of phenprocoumon is approximately 5 to 7 days (range 3-10 days). This long half-life results in sustained anticoagulant effect over days, requiring careful monitoring and dose adjustments.
Terminal elimination half-life: 5–9 hours in young adults, 11–13 hours in elderly (≥65 years). Clinical context: Twice-daily dosing due to relatively short half-life; renal impairment prolongs half-life (up to 15 hours in severe impairment).
Phenprocoumon is excreted primarily via renal elimination as metabolites (approximately 60-70% of the dose), with about 20% excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Renal (36% as unchanged drug, 30% as inactive metabolites), fecal/biliary (33% as unchanged drug via hepatobiliary route). Total clearance is 10 L/h.
Category C
Category C
Anticoagulant
Anticoagulant